Global assessment of insulin and oral hypoglycaemic agent accessibility and affordability: A cross-sectional survey of international diabetes federation member countries

Key Points

• Accessibility of insulin and oral hypoglycaemic agents varies widely among surveyed countries, impacting treatment options.
• Survey results revealed that 45% of countries reported high costs for insulin, with individual out-of-pocket expenses averaging $50 per month.
• Cross-sectional survey conducted across 80 countries that are part of the International Diabetes Federation.
• These findings underscore significant disparities in medication access, warranting urgent policy interventions to improve affordability.